Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune ...

Fabrice Chouraqui, Chief Executive Officer of Pharming, commented: ...

Dutch biopharma company Pharming Group saw its shares tumble 13.5% to 1.48 euros this morning after it received a regulatory ...

Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.

Biotech stock Pharming was pummeled Monday after the FDA rejected the company's request to expand the patient pool for Joenja ...

Shares of Pharming Group fell after the Food and Drug Administration requested more information from the company on Joenja, its candidate to treat a rare immunodeficiency in children. Shares were down ...

FDA issued a CRL to Pharming's Joenja child use filing, citing dosing concerns in lower-weight kids and testing issues.

Pharming Group (ENXTAM:PHARM) is back in focus after the US FDA issued a Complete Response Letter for its Joenja supplemental filing in children with APDS, asking for more dosing and testing data. See ...

Pharming Group (NASDAQ:PHAR) outlined its 2026 financial guidance and provided updates on its commercial portfolio and late-stage pipeline during its 2026 Investor Day, emphasizing continued revenue ...

Joenja is a sizeable contributor to Pharming's revenues, accounting for €38 million ($45 million) of its total sales of €70 ...

CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao Pharming's dismissal did not involve any fault, liability, or penalties against Pharming ...